U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07267026) titled 'A Study to Evaluate the Safety, Tolerability and PK of SK-09' on Nov. 17.
Brief Summary: This Phase 1 trial consists of two parts: Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study. Both parts adopt a randomized, double-blind, placebo-controlled design.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
FSGS
MCD
Intervention:
DRUG: SK-09
Dose groups of 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 500 mg were given.
DRUG: Placebo
Dose groups of 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 500 mg were given.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Consun Pharmac...